What does the research say about Spliceosome CHIP?

Spliceosome CHIP

There is 1 paper on spliceosome CHIP in aging research: 1 observational study in people. The newest story, Oct 26, 2026: “Blood mutations linked to heart, kidney, and metabolic disease”.

Biomarker

1 paper studies it2 more mention it1 finding

1 new paper in 30 daysSee all 3

“spliceosome CHIP (aHR, 1.50; 95% CI, 1.25-1.80; P<0.001)”

Association of clonal hematopoiesis with cardiovascular-kidney-metabolic syndrome in 434,000 individualsESC Congress 2026 abstract2026doi:10.1093/eurheartj/ehag785.3109

Humans1

Associations

Progression to stage 4 cardiovascular-kidney-metabolic syndrome

upin humans1HR 1.5

1 study

Spliceosome CHIP is associated with progression to stage 4 cardiovascular-kidney-metabolic syndrome in humans (CKM stages 0–3 at baseline) (Adjusted HR 1.50, 95% CI 1.25–1.80; P<0.001).
“spliceosome CHIP (aHR, 1.50; 95% CI, 1.25-1.80; P<0.001)”
HumansCKM stages 0–3 at baselineMedian follow-up of 13.6 years
Blood mutations linked to heart, kidney, and metabolic disease
ESC Congress 2026 abstractOct 26, 2026

More on Progression to stage 4 cardiovascular-kidney-metabolic syndrome

Latest

2 papers in 12 months

ESC Congress 2026 AbstractOct 26

Blood mutations linked to heart, kidney, and metabolic disease

Participants with age-related expansion of mutated blood cells had an adjusted hazard ratio of 1.11 for progression to syndrome stage 4 compared with participants without…Participants with age-related expansion of mutated blood cells had an adjusted hazard ratio of 1.11 for progression to syndrome stage 4 compared with participants without the condition.

Cohort · 433,924 peopleStage 4 cardiovascular-kidney-metabolic syndrome

Paper

JAMA CardiologyNov 9